Earnings summaries and quarterly performance for Alector.
Executive leadership at Alector.
Board of directors at Alector.
Research analysts who have asked questions during Alector earnings calls.
MM
Myles Minter
William Blair & Company
3 questions for ALEC
Also covers: ALNY, ARCT, ARGX +12 more
Alec Stranahan
Bank of America
2 questions for ALEC
Also covers: AGIO, BEAM, BTAI +12 more
Ananda Ghosh
H.C. Wainwright & Co.
2 questions for ALEC
Also covers: ABOS, AMLX, PEPG +1 more
CL
Carter L. Gould
Barclays
2 questions for ALEC
Also covers: ABBV, AMGN, BMY +8 more
JH
Jeff Hung
Morgan Stanley
2 questions for ALEC
Also covers: ACAD, BHVN, BLUE +10 more
PS
Pete Stavropoulos
Cantor Fitzgerald
2 questions for ALEC
Also covers: ABOS, ARCT, AXSM +9 more
Thomas Shrader
BTIG
2 questions for ALEC
Also covers: ABOS, ARCT, CMPS +8 more
YW
Yaron Werber
TD Cowen
2 questions for ALEC
Also covers: AMGN, ARGX, ASND +15 more
Corinne Jenkins
Goldman Sachs
1 question for ALEC
Also covers: ACRS, ATHA, FULC +7 more
DM
Douglas Macpherson
Mizuho Securities
1 question for ALEC
Also covers: QSI, XFOR
E
Emily
Stifel
1 question for ALEC
Graig Suvannavejh
Mizuho Securities
1 question for ALEC
Also covers: ADAP, ADVM, AMLX +12 more
JP
Julian Pino
Jefferies
1 question for ALEC
Also covers: ACAD, ALKS, ALNY +3 more
Michael Riad
Morgan Stanley
1 question for ALEC
Also covers: ACAD, ITCI, JAZZ +3 more
SS
Samantha Schaeffer
Cantor Fitzgerald
1 question for ALEC
Also covers: ARCT
SS
Sarah Schram
William Blair
1 question for ALEC
Also covers: XENE
SA
Steven Ayanov
TD Securities
1 question for ALEC
Tom Shrader
BTIG
1 question for ALEC
Also covers: ABOS, ALDX, ESPR +4 more
Recent press releases and 8-K filings for ALEC.
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ALEC
Earnings
Guidance Update
New Projects/Investments
- Alector reported collaboration revenue of $6.2 million and a net loss of $37.3 million for the fourth quarter ended December 31, 2025. For the full year 2025, collaboration revenue was $21.0 million, and the net loss was $142.9 million.
- As of December 31, 2025, the company's cash, cash equivalents, and investments totaled $256.0 million, which is expected to provide a financial runway at least through 2027.
- Key pipeline updates include an expected IND application for AL137 in Q4 2026 / Q1 2027, a targeted IND application for AL050 in 2027, and an independent interim futility analysis for the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) anticipated in the first half of 2026.
2 days ago
Alector Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
ALEC
Earnings
Guidance Update
New Projects/Investments
- Alector reported a net loss of $37.3 million for the fourth quarter of 2025 and a net loss of $142.9 million for the full year 2025.
- As of December 31, 2025, the company held $256.0 million in cash, cash equivalents, and investments, which is expected to fund operations at least through 2027.
- An independent interim futility analysis for the PROGRESS-AD Phase 2 trial of nivisnebart (AL101) in early Alzheimer’s disease is anticipated in the first half of 2026.
- Alector expects to file an Investigational New Drug (IND) application for AL137 in Q4 2026 / Q1 2027 and targets an IND submission for AL050 in 2027.
2 days ago
Alector's Phase 3 INFRONT-3 Trial Misses Co-Primary Endpoint, Leading to Investigation
ALEC
Legal Proceedings
Demand Weakening
- Alector, Inc. (ALEC) is under investigation by Levi & Korsinsky, LLP following the announcement of topline results from its Phase 3 INFRONT-3 trial.
- The Phase 3 INFRONT-3 trial for latozinemab, evaluating its efficacy in slowing progression of frontotemporal dementia (FTD-GRN), failed to achieve its clinical co-primary endpoint.
- While the biomarker response co-primary endpoint was met, the clinical response endpoint was not met, leading analysts to express disappointment and downgrade ALEC's stock after the results were reported on October 21, 2025.
Jan 29, 2026, 11:06 PM
Alector Therapeutics discusses pipeline and financial runway at BofA 2025 CNS conference
ALEC
New Projects/Investments
Guidance Update
- Alector Therapeutics is focused on developing therapeutics for neurodegenerative disorders, leveraging its proprietary Blood-Brain Barrier (BBB) technology to enhance drug delivery to the brain.
- The company's pipeline includes a progranulin-elevating drug (AL101) in Phase 2 for Alzheimer's disease, with an interim analysis expected in the first half of 2026.
- Alector is also advancing an anti-amyloid beta antibody (AL137) targeting the clinic in 2026, and a GCase enzyme replacement therapy (AL50) for Parkinson's disease, with first-in-human studies targeted for 2027.
- The company reported approximately $300 million in cash, providing a financial runway through 2027 to support its clinical programs and achieve multiple value-creating milestones.
Dec 8, 2025, 7:25 PM
Alector Therapeutics Provides Pipeline Update and Financial Outlook
ALEC
Product Launch
New Projects/Investments
Guidance Update
- Alector Therapeutics, a neurodegeneration-focused company, expects an interim analysis of its Phase 2 study for AL101, a progranulin-elevating drug for Alzheimer's disease partnered with GSK, in the first half of 2026.
- The company's ABC platform utilizes blood-brain barrier technology to deliver large molecules to the brain at 10- to 50-fold higher concentrations, aiming for enhanced efficacy, lower dosing, and improved safety for neurodegenerative disorders.
- Alector plans to advance its anti-amyloid beta antibody (AL137) into the clinic in 2026 and its GCase enzyme replacement therapy (AL50) for Parkinson's disease into first-in-human studies in 2027, both leveraging the ABC platform.
- With approximately $300 million in cash, Alector has a financial runway through 2027 and anticipates achieving multiple value-creating milestones, including patient data for AL137, within this period.
Dec 8, 2025, 7:25 PM
Alector Therapeutics Provides Pipeline and Financial Updates
ALEC
New Projects/Investments
Guidance Update
- Alector Therapeutics, a neurodegeneration-focused company, anticipates an interim analysis for its Phase II AL101 study in Alzheimer's disease during H1 2026.
- The company's Blood-Brain Barrier (ABC) platform is advancing new programs, including an anti-amyloid-β antibody (AL137) expected to enter the clinic in 2026 and a GCase enzyme replacement therapy (AL50) for Parkinson's disease targeting first-in-human studies in 2027.
- Alector reports a cash runway through 2027 with approximately $300 million in cash, which is expected to support multiple value-creating milestones across its clinical and preclinical programs.
Dec 8, 2025, 7:25 PM
Alector Reports Q3 2025 Financial Results and Strategic Business Updates
ALEC
Earnings
Layoffs
Guidance Update
- Alector reported a net loss of $34.7 million, or $0.34 per share, for the third quarter of 2025. As of September 30, 2025, the company had $291.1 million in cash, cash equivalents, and investments, which is anticipated to fund operations through 2027.
- In October 2025, Alector implemented a reduction in force of approximately 47% to focus resources and extend its cash runway.
- The company is advancing lead candidates AL137 and AL050 toward IND-enabling studies, targeting IND submissions in 2026 and 2027, respectively.
- Topline results from the Phase 3 clinical trial for latozinemab in frontotemporal dementia due to a GRN gene mutation did not demonstrate clinical benefit, leading to the discontinuation of the trial. An independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebart is planned for the first half of 2026.
Nov 6, 2025, 9:12 PM
Alector Reports Third Quarter 2025 Financial Results and Business Updates
ALEC
Earnings
Layoffs
Guidance Update
- Alector reported a net loss of $34.7 million, or $0.34 per share, for the third quarter ended September 30, 2025, with collaboration revenue of $3.3 million.
- The company's cash, cash equivalents, and investments totaled $291.1 million as of September 30, 2025, providing a runway through 2027.
- Alector is advancing lead candidates AL137 and AL050 toward IND-enabling studies, with IND filings targeted for 2026 and 2027, respectively, and an independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101) is planned for 1H 2026.
- In October 2025, the company implemented a workforce reduction of approximately 47% and discontinued the INFRONT-3 Phase 3 clinical trial for latozinemab due to a lack of clinical benefit.
Nov 6, 2025, 9:05 PM
Alector Announces Negative Phase 3 Clinical Trial Results for Latozinemab
ALEC
New Projects/Investments
- Biotechnology company Alector announced that its drug, latozinemab, failed to meet safety and efficacy criteria in a Phase 3 clinical trial for cases of FTD caused by a GRN gene variant.
- While the treatment resulted in a significant increase in plasma PGRN levels, it did not slow the progression of the disease as measured by clinical co-primary endpoints or affect biological markers of disease progression.
- Based on these results, Alector has concluded the study, and the open-label extension portion of the trial and the continuation study will both be discontinued.
Oct 21, 2025, 10:45 PM
Alector's Latozinemab Phase 3 Trial Fails to Meet Primary Endpoint
ALEC
Layoffs
Profit Warning
- Alector's Phase 3 INFRONT-3 trial for latozinemab, targeting frontotemporal dementia (FTD) caused by GRN gene mutations, failed to meet its primary clinical endpoint of slowing disease progression.
- Despite the drug significantly increasing plasma progranulin levels, it did not translate into clinical benefit or affect other biomarkers.
- In response to the trial failure, Alector announced it would terminate the open-label extension of the trial and lay off 49% of its 238 employees.
- The 96-week double-blind study, conducted in collaboration with GSK, found the treatment to be safe with no major adverse events reported.
Oct 21, 2025, 9:53 PM
Quarterly earnings call transcripts for Alector.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more